Latest stories on OCUL
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy
Investing.com Analyst Ratings61 · neutralanalyst
Ocular Therapeutix completes pre-NDA meeting with FDA for Axpaxli
The Fly63 · neutralproduct/pr
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
StockTitan73 · bullishproduct/pr
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
GlobeNewswire73 · bullishproduct/pr
Ace Therapeutics Expands Customized Ocular Drug Delivery Services to Support Ophthalmic Drug Development
Barchart59 · neutralproduct/pr
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
GlobeNewswire63 · neutralproduct/pr
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
Business Insider63 · neutralproduct/pr
Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs
Yahoo Top53 · neutralgeneral
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
StockTitan56 · neutralgeneral
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
GlobeNewswire56 · neutralgeneral
Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
Seeking Alpha63 · neutralproduct/pr
Clear Street sees less competition for Ocular after EyePoint miss
The Fly58 · neutralanalyst
Ocular gains on EyePoint phase 3 wet AMD miss
Seeking Alpha38 · neutralgeneral
Why is Ocular Therapeutix stock rallying today?
Investing.com Markets50 · neutralgeneral
Ocular Therapeutix rises 10.4%
The Fly58 · neutralgeneral
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
NovelMed Advances Its Ocular Program, Highlighting the Potential of a Single Therapy Across Multiple Retinal Diseases
Business Insider63 · neutralproduct/pr
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat
Seeking Alpha67 · bullishproduct/pr
OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights
Stocktwits News58 · neutralearnings
Ocular Therapeutix GAAP EPS of -$0.35 beats by $0.04, revenue of $13.48M beats by $0.28M
Seeking Alpha63 · neutralearnings